{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T07:10:07Z","timestamp":1717657807845},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00393-017-0327-z","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T04:36:24Z","timestamp":1495514184000},"page":"40-45","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rituximab zur Behandlung von Poly- und Dermatomyositis"],"prefix":"10.1007","volume":"77","author":[{"given":"C.","family":"Fiehn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Proft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Henes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jacobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"327_CR1","first-page":"1369","volume":"32","author":"O Lambotte","year":"2005","unstructured":"Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF (2005) Efficacy of rituximab in refractory polymyositis. J\u00a0Rheumatol 32:1369\u20131370","journal-title":"J Rheumatol"},{"key":"327_CR2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2005.045898","volume":"65","author":"L Brulhart","year":"2006","unstructured":"Brulhart L, Waldburger JM, Gabay C (2006) Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 65:974\u2013975","journal-title":"Ann Rheum Dis"},{"key":"327_CR3","first-page":"887","volume":"26","author":"SM Sultan","year":"2008","unstructured":"Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G (2008) Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 26:887\u2013893","journal-title":"Clin Exp Rheumatol"},{"key":"327_CR4","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","volume":"48","author":"M Sem","year":"2009","unstructured":"Sem M, Molberg \u00d8, Lund MB, Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome \u2013 a\u00a0retrospective case series. Rheumatology 48:968\u2013971","journal-title":"Rheumatology"},{"key":"327_CR5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/2049-6958-6-3-183","volume":"6","author":"MC Zappa","year":"2011","unstructured":"Zappa MC, Trequattrini T, Mattioli F, Rivitti R, Vigliarolo R, Marcoccia A et\u00a0al (2011) Rituximab treatment in a\u00a0case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure. Multidiscip Respir Med 6:183\u2013188","journal-title":"Multidiscip Respir Med"},{"key":"327_CR6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","volume":"54","author":"H Andersson","year":"2015","unstructured":"Andersson H, Sem M, Lund MB, Aalokken TM, G\u00fcnther A, Walle-Hansen R et al (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 54:1420\u20131428","journal-title":"Rheumatology (Oxford)"},{"key":"327_CR7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, RIM Study Group. (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a\u00a0randomized, placebo-phase trial. Arthritis Rheumatol 65:314\u2013324","journal-title":"Arthritis Rheumatol"},{"key":"327_CR8","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, K\u00f6tter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, M\u00fcller-Ladner U, K\u00f6nig R, Fiehn C, Burgwinkel P, Budde K, S\u00f6rensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, D\u00f6rner T, GRAID investigators (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a\u00a0national registry (GRAID). Arthritis Res Ther 13:R75","journal-title":"Arthritis Res Ther"},{"key":"327_CR9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC, RIM Study Group. (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66:740\u2013749","journal-title":"Arthritis Rheumatol"},{"key":"327_CR10","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","volume":"43","author":"J Bauhammer","year":"2016","unstructured":"Bauhammer J, Blank N, Max R, Lorenz HM, Wagner U, Krause D, Fiehn C (2016) Rituximab in the treatment of Jo1 antibody-associated Antisynthetase syndrome: anti-Ro52 Positivity as a\u00a0marker for severity and treatment response. J\u00a0Rheumatol 43:1566\u20131574","journal-title":"J Rheumatol"},{"key":"327_CR11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/ddg.12909","volume":"14","author":"C Sunderk\u00f6tter","year":"2016","unstructured":"Sunderk\u00f6tter C, Nast A, Worm M, Dengler R, D\u00f6rner T, Ganter H, Hohlfeld R, Melms A, Melzer N, R\u00f6sler K, Schmidt J, Sinnreich M, Walter MC, Wanschitz J, Wiendl H (2016) Guidelines on dermatomyositis \u2013 excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J\u00a0Dtsch Dermatol Ges 14:321\u2013338","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-017-0327-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0327-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0327-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T03:21:31Z","timestamp":1517800891000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-017-0327-z"}},"subtitle":["Die Ergebnisse des GRAID-2-Registers"],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1007\/s00393-017-0327-z","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}